Skip to research
Margin Monkey THEMARGINMONKEY Start my free trialTry free

Neogen (NEOG) stock in plain English

Free brief · no signupStart here
NEOGPublished Nov 17, 2026
Neogen Corp
Healthcare · Medical Devices
Manufactures diagnostic test kits and genetic screening tools for food processors and farmers.
Assets:
Genomics laboratoriesFacilities in Lincoln, Nebraska and Scotland process millions of agricultural DNA samples annually.
Global manufacturing networkProduction sites across the United States, United Kingdom, and Brazil supply testing media.
Over 2,800 employeesStaff spread across international sales offices, manufacturing plants, and certified diagnostic laboratories.
Locked assetIn the full report
Rated Nov 19, 2026

Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.

63
OPS ScoreOperating finances
Latest quote
-2.08%$10.85
$2.37B
n/a (loss)
$883.81M

Change shown by the quote provider. Data may be delayed.

Financial statements, in plain wordsSales, profit, debt and cash, year by year
Published Nov 17, 2026Quotes updated Nov 20, 04:10 UTCOPS Score, TMM Score and the rating are research summaries, not advice or forecasts.
That was NEOG. The desk has 1,900+ more companies.Each one comes with its scores, its flags and the sources behind them.
7 days free · No card

What does Neogen (NEOG) do?

Neogen Corp (NEOG) is a U.S.-listed company in Healthcare (Medical Devices). What it does: Manufactures diagnostic test kits and genetic screening tools for food processors and farmers. Makes diagnostic test kits and genomic tools for food safety and animal health across agriculture supply chains. It is worth $2.37B on the market and sold $883.81M over the last year.

Market cap
$2.37B
P/E ratio
None (reported a loss)
Annual sales
$883.81M
Sector
Healthcare
Industry
Medical Devices
Brief updated
Nov 17, 2026

Brands and businesses behind NEOG

  • Petrifilm: Sells ready-to-use sample plates that culture and enumerate bacteria for commercial food safety testing.
  • Igenity: Provides commercial genomic profiling tests for cattle producers to assess herd health, growth potential, and breeding traits.
  • Reveal: Produces rapid lateral flow test strips that detect foodborne pathogens and allergens in food processing environments.
  • Megazyme: Manufactures enzymatic assay kits and analytical reagents used in dietary fiber, carbohydrate, and beverage testing laboratories.

NEOG’s flags, in plain English

Each flag is a number from Neogen’s reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 17, 2026.

Stupid Cash

Can pay this year's bills 3.9 times over. Cash in the bank covers a long stretch of running costs. The company can fund itself without borrowing or selling new shares.

Low debt

Low debt, only 37% of shareholder equity. The company owes very little compared with what it earns, so a bad year is less likely to force its hand.

Still Climbing

Sales up 13.2% a year over 5 years. Sales are higher than a year ago. Growth does not guarantee profit, so look at the margins too.

Burning Cash

Losing money, profit margin of -6.4%. The business spends more cash than it brings in. It has to cover the gap with cash on hand, new loans or new shares.

1 more green flag open with the free trial. Try it free for 7 days.

Questions about NEOG

How big is Neogen?

Neogen’s market cap is $2.37B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $883.81M: what customers paid the company over the last year, before any costs.

What is NEOG’s P/E ratio?

NEOG has no P/E ratio right now. The company reported a loss, so there is no yearly profit to price.

What could go wrong with NEOG?

The company carries substantial debt from acquiring 3M's food safety division while continuing to manage complex operational integration work. That is one risk on Neogen’s card. Its first risk flag is Burning Cash, explained above. A flag reads what the company reported. It does not predict the price.

Where do these numbers come from?

From Neogen’s own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. NEOG’s filings on SEC.gov. The Margin Monkey is research, not advice.

Your first 7 days are free.Search all 1,900+ companies and open every card. Members also get the ratings, Picks and the TMM Score.
7 days free · No card